VITIELLO, PAOLA

VITIELLO, PAOLA  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 14 di 14 (tempo di esecuzione: 0.003 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation 2-gen-2020 Di Cristo, ValentinaVitiello, PaolaCossu, Maria VittoriaColella, ElisaRusconi, Stefano + Article (author) -
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens 1-gen-2011 O. ViganòS. FerramoscaP. VitielloM. GalliS. Rusconi + Article (author) -
Determinants of virological response to raltegravir (RAL)-containing regimens and prevalence of RAL-resistance associated mutations at failure in ARCA 1-mar-2010 S. RusconiP. Vitiello + Article (author) -
Does GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results 1-gen-2011 M. OrtuP. VitielloO. ViganòM. GalliS. Rusconi + Article (author) -
Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART 10-giu-2010 S. RusconiP. VitielloS. FerramoscaE. MerliniG. Marchetti + Article (author) -
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir 1-gen-2008 B. VerganiLO CICERO, MIRKOO. ViganòS. FerramoscaP. VitielloDI VINCENZO, PAOLAM. GalliS. Rusconi + Article (author) -
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database 1-gen-2013 S. RusconiP. Vitiello + Article (author) -
Levofloxacin-induced seizures in a patient without predisposing risk factors : the impact of pharmacogenetics 1-ago-2013 D. CattaneoF.S. FalvellaP. VitielloS. CheliE. ClementiA. Riva + Article (author) -
Maraviroc : un inibitore del co-recettore CCR5 con un unico profilo di efficacia e tollerabilita’ in diversi scenari clinici dell'infezione da HIV-1 1-set-2012 S. RusconiE. ColellaP. Vitiello Article (author) -
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial 14-nov-2013 S. RusconiP. VitielloE. ColellaA. CapettiF. BaiM. MorosiP. TauE. MerliniG. Marchetti + Article (author) -
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART 8-nov-2010 S. RusconiP. VitielloE. ColellaE. MerliniG.C. Marchetti + Article (author) -
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA) 1-gen-2010 P. Di VincenzoS. RusconiP. VitielloC. F. Perno + Article (author) -
Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature 1-gen-2010 F. CroceP. VitielloDALLA PRIA, ALESSIAA. RivaM. GalliS. Antinori Article (author) -
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides 1-nov-2016 Riccardi N.Taramasso L.Capetti A.Vitiello P. + Article (author) -